Summary & Overview
CPT 0534U: PROSTOX™ ultra - Genitourinary Toxicity Risk Score
CPT code 0534U designates PROSTOX™ ultra, a Proprietary Laboratory Analyses (PLA) test by MiraDx Inc. that evaluates 32 genetic markers (microRNAs and SNPs) via RT–PCR to produce a risk score for genitourinary toxicity after radiation therapy. The code is significant nationally as precision oncology and personalized toxicity risk profiling influence treatment planning and shared decision-making for patients undergoing prostate-directed radiation.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test’s clinical purpose, typical service and site-of-service settings, and the policy and reimbursement context relevant to proprietary lab tests. The publication summarizes payer coverage trends, coding and billing considerations for PLA codes, and clinical context on how a molecular risk score may be used to inform radiation planning.
The report is designed to inform billing and compliance professionals, laboratory administrators, and clinicians about the role of CPT code 0534U in documenting PROSTOX™ ultra testing, expected sites of service, and where to look for payer-specific policy details. Data not available in the input will be noted as such in the detailed sections.
Billing Code Overview
CPT code 0534U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the PROSTOX™ ultra test from MiraDx Inc. The test analyzes 32 genetic variants, including microRNAs and single–nucleotide polymorphisms (SNPs), using reverse transcription polymerase chain reaction (RT–PCR) and generates a risk score that estimates the likelihood of genitourinary toxicity following radiation therapy.
Service type: Proprietary laboratory genetic risk assessment using RT–PCR
Typical site of service: Clinical laboratory or contracted specialty lab; specimen collection in outpatient clinic or hospital outpatient setting
Clinical & Coding Specifications
Clinical Context
A 68-year-old man with localized prostate adenocarcinoma is scheduled to receive external beam radiation therapy. The radiation oncology team orders the PROSTOX™ ultra test (0534U) from MiraDx Inc. prior to treatment planning to assess the patient’s genetic risk of developing genitourinary (GU) toxicity after radiation. A peripheral blood sample is collected in the outpatient oncology clinic or hospital laboratory and sent to the manufacturer’s laboratory. The lab performs reverse transcription polymerase chain reaction (RT–PCR) to analyze 32 genetic variants, including microRNAs and single–nucleotide polymorphisms (SNPs). The test returns a risk score indicating low, intermediate, or high likelihood of post-radiation GU toxicity. The treating radiation oncologist reviews the result during treatment planning to inform dose constraints, fractionation decisions, and discussion of anticipated side effects with the patient. Typical sites of service for ordering, sample collection, and care coordination include outpatient radiation oncology clinics, hospital outpatient departments, and clinical laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity for specimen collection or documentation is substantially greater than typical for this test and supporting documentation is appended. |